Rep. April McClain Delaney Buys Laboratory Co. of America Holdings (NYSE:LH) Shares

Representative April McClain Delaney (D-Maryland) recently bought shares of Laboratory Co. of America Holdings (NYSE:LH). In a filing disclosed on March 20th, the Representative disclosed that they had bought between $1,001 and $15,000 in Laboratory Co. of America stock on February 28th.

Representative April McClain Delaney also recently made the following trade(s):

• Sold $15,001 – $50,000 in shares of Revvity (NYSE:RVTY) on 2/28/2025.
• Purchased $15,001 – $50,000 in shares of Corpay (NYSE:CPAY) on 2/28/2025.
• Sold $1,001 – $15,000 in shares of Tempur Sealy International (NYSE:TPX) on 2/28/2025.
• Purchased $1,001 – $15,000 in shares of CACI International (NYSE:CACI) on 2/27/2025.
• Purchased $1,001 – $15,000 in shares of Laboratory Co. of America (NYSE:LH) on 2/27/2025.
• Purchased $1,001 – $15,000 in shares of Paychex (NASDAQ:PAYX) on 2/27/2025.
• Sold $15,001 – $50,000 in shares of Teledyne Technologies (NYSE:TDY) on 2/22/2025.
• Purchased $1,001 – $15,000 in shares of Corpay (NYSE:CPAY) on 2/22/2025.
• Sold $1,001 – $15,000 in shares of Tempur Sealy International (NYSE:TPX) on 2/22/2025.
• Sold $1,001 – $15,000 in shares of CACI International (NYSE:CACI) on 2/22/2025.

Laboratory Co. of America Price Performance

Shares of NYSE:LH opened at $233.97 on Friday. The company’s fifty day moving average price is $245.16 and its 200-day moving average price is $234.28. The firm has a market capitalization of $19.58 billion, a price-to-earnings ratio of 26.53, a PEG ratio of 1.71 and a beta of 1.12. Laboratory Co. of America Holdings has a one year low of $191.97 and a one year high of $258.59. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.44 and a quick ratio of 1.30.

Laboratory Co. of America (NYSE:LH) last posted its quarterly earnings results on Thursday, February 6th. The medical research company reported $3.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.40 by $0.05. Laboratory Co. of America had a net margin of 5.73% and a return on equity of 15.29%. On average, equities research analysts anticipate that Laboratory Co. of America Holdings will post 16.01 earnings per share for the current fiscal year.

Laboratory Co. of America Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, March 12th. Investors of record on Thursday, February 27th were issued a dividend of $0.72 per share. The ex-dividend date of this dividend was Thursday, February 27th. This represents a $2.88 dividend on an annualized basis and a yield of 1.23%. Laboratory Co. of America’s dividend payout ratio (DPR) is 32.65%.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on LH shares. StockNews.com upgraded Laboratory Co. of America from a “hold” rating to a “buy” rating in a report on Friday, February 7th. Morgan Stanley boosted their target price on Laboratory Co. of America from $260.00 to $270.00 and gave the company an “overweight” rating in a research note on Tuesday, December 17th. UBS Group dropped their price target on Laboratory Co. of America from $293.00 to $286.00 and set a “buy” rating for the company in a research note on Tuesday, January 28th. Jefferies Financial Group boosted their price objective on shares of Laboratory Co. of America from $275.00 to $290.00 and gave the company a “buy” rating in a research report on Thursday, February 6th. Finally, Bank of America upped their price objective on shares of Laboratory Co. of America from $262.00 to $271.00 and gave the stock a “buy” rating in a report on Friday, December 13th. Three research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Laboratory Co. of America presently has a consensus rating of “Moderate Buy” and an average price target of $268.38.

Insider Transactions at Laboratory Co. of America

In related news, CEO Adam H. Schechter sold 6,121 shares of the stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $244.62, for a total transaction of $1,497,319.02. Following the transaction, the chief executive officer now owns 86,445 shares in the company, valued at $21,146,175.90. This represents a 6.61 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Kerrii B. Anderson sold 1,000 shares of Laboratory Co. of America stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $235.00, for a total transaction of $235,000.00. Following the completion of the sale, the director now directly owns 12,722 shares of the company’s stock, valued at approximately $2,989,670. This trade represents a 7.29 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 14,500 shares of company stock worth $3,577,572. Corporate insiders own 0.85% of the company’s stock.

Hedge Funds Weigh In On Laboratory Co. of America

Several large investors have recently made changes to their positions in the business. Graney & King LLC bought a new stake in Laboratory Co. of America in the fourth quarter worth $26,000. SouthState Corp bought a new position in Laboratory Co. of America in the 3rd quarter worth about $28,000. Fortitude Family Office LLC boosted its stake in Laboratory Co. of America by 312.5% in the 4th quarter. Fortitude Family Office LLC now owns 132 shares of the medical research company’s stock worth $30,000 after purchasing an additional 100 shares in the last quarter. Geneos Wealth Management Inc. increased its stake in Laboratory Co. of America by 309.8% during the 4th quarter. Geneos Wealth Management Inc. now owns 168 shares of the medical research company’s stock valued at $39,000 after purchasing an additional 127 shares in the last quarter. Finally, Human Investing LLC purchased a new position in Laboratory Co. of America in the fourth quarter worth about $39,000. 95.94% of the stock is currently owned by hedge funds and other institutional investors.

About Representative McClain Delaney

April McClain-Delaney (Democratic Party) is a member of the U.S. House, representing Maryland’s 6th Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

McClain-Delaney (Democratic Party) is running for re-election to the U.S. House to represent Maryland’s 6th Congressional District. She declared candidacy for the 2026 election.

April McClain-Delaney grew up in Buhl, Idaho, where her father was a potato farmer. She obtained her bachelor’s degree in communications from Northwestern University in 1986 and her law degree from Georgetown Law Center in 1989. McClain-Delaney worked in communications law, first with the satellite firm Orion Network Systems and later as the Washington director for Common Sense Media, a nonprofit focused on technology and children. In 2022, McClain-Delaney joined the U.S. Department of Commerce under President Joe Biden (D) as deputy assistant secretary for communications and information. McClain-Delaney served on the board of the Georgetown University Law Center, the International Center for Research on Women, and the Northwestern University School of Communications.

Laboratory Co. of America Company Profile

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.